Maryana Simonova

450 total citations
4 papers, 29 citations indexed

About

Maryana Simonova is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Maryana Simonova has authored 4 papers receiving a total of 29 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Hematology, 2 papers in Molecular Biology and 2 papers in Oncology. Recurrent topics in Maryana Simonova's work include Multiple Myeloma Research and Treatments (3 papers), Cancer Treatment and Pharmacology (2 papers) and Protein Degradation and Inhibitors (2 papers). Maryana Simonova is often cited by papers focused on Multiple Myeloma Research and Treatments (3 papers), Cancer Treatment and Pharmacology (2 papers) and Protein Degradation and Inhibitors (2 papers). Maryana Simonova collaborates with scholars based in France, United Kingdom and Greece. Maryana Simonova's co-authors include Iryna Kryachok, Sosana Delimpasi, Roman Hájek, Vadim Doronin, Xavier Leleu, Dinesh Kumar Sinha, Meletios Α. Dimopoulos, Holger W. Auner, Luděk Pour and Halyna Pylypenko and has published in prestigious journals such as Journal of Clinical Oncology and Experimental Oncology.

In The Last Decade

Maryana Simonova

4 papers receiving 29 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maryana Simonova France	3	28	23	15	6	2	4	29
Edvan Crusoé Brazil	2	28 1.0×	18 0.8×	15 1.0×	8 1.3×	2 1.0×	4	29
Debbie Hastings United States	3	21 0.8×	20 0.9×	13 0.9×	7 1.2×	3 1.5×	7	30
Brianna Berrios United States	3	26 0.9×	21 0.9×	15 1.0×	4 0.7×	1 0.5×	4	37
Melina Arazy United States	2	36 1.3×	32 1.4×	22 1.5×	4 0.7×	3 1.5×	2	37
Olga Shvetz Israel	3	22 0.8×	19 0.8×	16 1.1×	4 0.7×		6	26
Lydia Eccersley United Kingdom	3	20 0.7×	17 0.7×	13 0.9×	5 0.8×		9	28
Daniela V. Wenge United States	6	37 1.3×	38 1.7×	13 0.9×	5 0.8×		12	60
Carolina Lonardi United States	3	23 0.8×	20 0.9×	28 1.9×	4 0.7×		14	36
Cécile Sonntag France	2	22 0.8×	19 0.8×	11 0.7×	3 0.5×		3	23
Juan Bargay Spain	3	33 1.2×	17 0.7×	12 0.8×	9 1.5×		4	38

Countries citing papers authored by Maryana Simonova

Since Specialization

Citations

This map shows the geographic impact of Maryana Simonova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maryana Simonova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maryana Simonova more than expected).

Fields of papers citing papers by Maryana Simonova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maryana Simonova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maryana Simonova. The network helps show where Maryana Simonova may publish in the future.

Co-authorship network of co-authors of Maryana Simonova

This figure shows the co-authorship network connecting the top 25 collaborators of Maryana Simonova. A scholar is included among the top collaborators of Maryana Simonova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maryana Simonova. Maryana Simonova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Simonova, Maryana, et al.. (2021). Erythropoietin as an independent prognostic factor in myelodysplastic syndromes. Experimental Oncology. 43(1). 41–45. 2 indexed citations

2.

Façon, Thierry, Holger W. Auner, Maria Gavriatopoulou, et al.. (2021). Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.. Journal of Clinical Oncology. 39(15_suppl). 8019–8019. 1 indexed citations

3.

Leleu, Xavier, María‐Victoria Mateos, Sundar Jagannath, et al.. (2021). Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.. Journal of Clinical Oncology. 39(15_suppl). 8024–8024. 4 indexed citations

4.

Dimopoulos, Meletios Α., Sosana Delimpasi, Maryana Simonova, et al.. (2020). Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.. Journal of Clinical Oncology. 38(15_suppl). 8501–8501. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact